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Introduction 
Ten years ago, describing what is new in phospholipid 
signaling in ten pages of Cell would have been easy; it 
would have been essentially a summary of the phospho- 
inositidase C (PIC) story: phosphatidylinositol(4,5)bisphos- 
phate (Ptdlns(4,5)P2) hydrolysis to inositiol(1,4,5)trisphos- 
phate (Ins(1",4,5)P3), with the synergistic action of Ca 2÷ 
(mobilized by Ins(1,4,5)P3) and diacylglycerol (DAG) on 
protein kinase C (PKC) (Table 1). As will become obvious 
below, the involvement of phospholipids in cell signaling is 
now enormously more complicated, and as more potential 
signaling systems emerge, it becomes even less clear as 
to which does what. With many of the systems, we are at 
a stage of ignorance similar to that in the late 1970's with 
PIC, confused and uncertain and largely lacking the tools 
and basic knowledge to build up the picture. So, with the 
limited space available we can make no attempt at com- 
prehensive coverage, but we will try to summarize, mostly 
by specific examples, what we see as the crucial questions 
as things stand now. The preceding sentence should be 
taken as a plea for tolerance from workers whose papers 
we have not cited and who consequently feel slighted. 
Inositol Lipids 
We will not discuss the regulation of the plasma mem- 
brane-located PIC signaling system here. Its enzymol- 
ogy and regulation and the enormous complexities of Ins 
(1,4,5)P3 action have been adequately dealt with in numer- 
ous reviews (Berridge, 1993; Rhee and Choi, 1992; Clap- 
ham, 1994 [this issue of Cell]). The big unknowns in inositol 
lipid function that we will deal with lie in three principal 
areas: 3-phosphorylated inositol lipids; Ptdlns(4,5)P2 and 
the cytoskeleton; and nuclear inositides. 
3.Phosphorylated Inositol Lipids 
This is the major inositide signaling system of the moment, 
to judge from investment of time and money. The cast of 
characters is shown in Figure 1, and there have been sev- 
eral extensive reviews recently (Stephens et al., 1993a; Ka- 
peller and Cantley, 1994). Although we still do not know 
what the physiological functions of 3-phosphorylated lipids 
are, there has been a considerable lifting of the mist sur- 
rounding them recently. One potential source of confusion 
that is just being clarified is the appearance that evolu- 
tion has had (at least) two bites at the 3-phosphorylated 
inositol lipid cherry: 3-phosphorylation of Ptdlns and of 
Ptdlns(4,5)P2 are probably controlled by different enzymes 
for different physiological functions. Let us make clear the 
distinction between a phosphoinositide 3-kinase (PI3- 
kinase) and a Ptdlns 3-kinase: the former can phosphory- 
late any inositol lipid in vitro, and we have to investigate 
by indirect means what substrate(s) it actually uses in the 
intact cell (as discussed below, the predominant substrate 
turns out to be Ptlns(4,5)P2). The latter enzyme is what it 
says, a Ptdlns-specific 3-kinase. 
Radiolalabeling experiments have shown that in intact 
cells, the principal route of Ptdlns(3,4,5)P3 synthesis is by 
3-phosphorylation of Ptdlns(4,5)P2 (Figure 1; Hawkins et 
al., 1992; Stephens et al., 1993a). Since many signal trans- 
duction pathways activate PI3-kinase, these experiments 
focus attention on Ptdlns(3,4,5)P3 as a potential second 
messenger. Although the possibility of an alternative route 
of Ptdlns(3,4,5)P3 synthesis in platelets has been described 
(Cunningham et al., 1990), recent experiments on the 
same tissue make this an unlikely possibility (Carter et al., 
1994). (The latter group labeled the cells for a very short 
time with 32p~ [i.e., nonequilibrium labeling], and this is 
critical for determination of inositide sythesis pathways 
by this method [Stephens and Downes, 1991]). The likeli- 
hood that PI3-kinase will in vivo phosphorylate mainly 
Ptdlns(4,5)P2, although in vitro it will phosphorylate Ptdlns, 
Ptdlns(4)P, and Ptdlns(4,5)P2, has remarkable parallels 
with properties of the PIC family; many of these show simi- 
lar differences in specificity between the test tube and the 
intact cell (Rhee and Choi, 1992). This parallel with PIC 
is further strengthened by the recent demonstration of a 
distinct PI3-kinase (presumably a Ptdlns(4,5)P2 3-kinase 
in vivo) that is not controlled through tyrosine kinase activ- 
ity, but rather by G proteins (Stephens et al., 1994a); the 
PIC enzymes can be classified into distinct families regu- 
lated by, for example, G proteins (13 family) and tyrosine 
kinases (7 family), and it is very likely that the PI3-kinases 
will show a similar type of grouping. 
The cloning of the catalytic subunit (p110) of mammalian 
PI3-kinase revealed homology with the yeast VPS34 gene 
(Hiles et al., 1992), which is involved in vacuolar protein 
processing (Herman and Emr, 1990). However, it was puz- 
zling that this yeast enzyme will only phosphorylate Ptdlns 
in the test tube and shows no activity against Ptdlns(4)P 
or Ptdlns(4,5)P2 (Kodaki et al., 1994a); this is consistent 
with the absence (thus far) of detectable Ptdlns(3,4,5)P3 
in yeast. What could have been a confusing picture has 
fortunately been clarified by Stephens et al. (1994b), who 
showed that mammalian cells also have a Ptdlns-specific 
3-kinase, distinct from the several other activities that will 
phosphorylate Ptdlns, Ptdlns(4)P, and Ptdlns(4,5)P=. It is 
a logical conclusion that this new enzyme is the true mam- 
malian vps34 homolog, and so it seems likely that what- 
ever function Ptdlns-3 phosphorylation serves in yeast, it 
probably still serves in animals and that the phosphoryla- 
tion of Ptdlns(4,5)P2 is for a different function that evolved 
after the split of yeast (and possibly also Chlamydomonas 
[Munnik et al., 1994]) from the animal evolutionary lineage. 
So, if Ptdlns(3)P and Ptdlns(3,4,5)P3 serve different 
functions, what of Ptdlns(3,4)P2; is it a mere breakdown 
product? A Ptdlns(3)P 4-kinase has been shown to be dis- 
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Table 1. Nomenclature: Present and Past 
Abbreviations 
Present Also Known As Definition 
PI Phosphoinositide 
PIC Phosphoinositidase C 
PI3-kinase PI3K Phosphoinositide 3-kinase 
Ptdlns Ptdl, PI Phosphatidylinositol 
Ptdlns(3)P PtdlnsP, PIP Phosphatidylinositol 3-phosphate 
Ptdlns(4,5)P2 PI(4,5)P2, PIP2 Phosphatidylinositol (4,5)bisphosphate 
Ptdlns(3,4,5)P3 PI(3,4,5)P3, PIP3 Phosphatidylinositol (3,4,5)trisphosphate 
PtdCho PC Phosphatidylcholine 
PtdEtn PE Phosphatidylethanolamine 
PtdOH PA Phosphatidic acid 
Ins(1,4)P2 IP2 Inositol (1,4)bisphosphate 
Ins(1,4,5)P3 IP3 Inositol (1,4,5)trisphosphate 
DAG Diacylglycerol 
PKC Protein kinase C 
PLC Phospholipase C
PLD Phospholipase D
The nomenclature used here makes clear the distinction between the general phosphoinositide and the specific phosphatidylinositol designation. 
The reasons for this are discussed in the text. Note that for reasons of history and journalistic style, molecules referenced in this study do not 
always follow this distinction. Other common abbreviations u ed have been noted. 
tinct from PI3-kinase or Ptdlns 4-kinase (Graziani et al., 
1992), and in a higher plant species, this route of synthesis 
of Ptdlns(3,4)P2 may be the predominant one (Brearly and 
Hanke, 1993). Thus, Ptdlns(3,4)P2 may have a role of its 
own, although this is still an open question. If Ptdlns(3)P 
has a role to play in vacuolar protein processing, what 
does Ptdlns(3,4,5)Ps do? This is not known yet either, but 
an enticing possibility has been suggested by Wennstr6m 
et al. (1994). Their data and those of others (Kotani et al., 
1994) imply the involvement of Ptdlns(3,4,5)P3 in mem- 
brane ruffling, and WennstrSm et al. (1994) have pointed 
out that the common factor in membrane ruffling (Rid- 
ley et al., 1992) and in two other processes in which 
Ptdlns(3,4,5)Ps is probably involved (e.g., superoxide gen- 
eration in neutrophils [Segal and Abo, 1993] and possibly 
glucose transport control in adipocytes) is the small G 
protein, rac. On this basis, Wennstr6m et al. (1994) 
have suggested that rac is a, or the, primary target of 
Ptdlns(3,4,5)Pa. 
PtdIns3P \ \ PtdIns(3,4)P 2 \ \ PtdIns(3,4,5)P 3 
Ptdlns \ \ PtdIns4P \ \ PtdIns(4,5)P 2 
Ins(1,4,5)P 3 + DAG 
F igure  1. Inositol Lipid Metabo l i sm 
Illustrated are the known inositol lipids, with all the interconversions 
that have been documented invitro (not all have been established in 
vivo yet). In bold are the three reactions believed to be rate limiting 
or receptor controlled: the 3-phosphorylation f Ptdlns (left), the 3-phos- 
phorylation ofPtdlns(4,5)P2 (right), and the hydrolysis of Ptdlns(4,5)P2 
by PIC (lower ight). 
Although increases in the 3-phosphorylated lipids has 
dominated the focus of research into the activation of this 
pathway, it should not be forgotten that the tyrosine ki- 
nase-stimulated PI3-kinase is a dual specificity enzyme. 
It is not only able to phosphorylate phosphoinositides, but 
it is also able to act as a serine/threonine protein kinase. 
This is demonstrated by p110-regulated phosphorylation 
of its own p85 regulatory subunit (Carpenter et al., 1993; 
Dhand et al., 1994). Initially, it was shown that phosphory- 
lating the 85 kDa subunit led to a decrease in the lipid 
3-kinase activity of the enzyme, so this was suggested as 
a mechanism for autoregulation. However, data in a recent 
paper by Lam et al. (1994) suggest that PI3-kinase, in an 
insulin-dependent fashion, is also able to phosphorylate 
insulin receptor 1. Whether the G protein-sensitive PI3- 
kinase will also turn out to be a serine/threonine kinase 
remains to be determined, but if not, this could potentially 
differentiate between the activation of the PI3-kinase path- 
way by G proteins versus its control by tyrosine kinases. 
To complicate matters further, two groups (Rodriguez- 
Viciana et al., 1994; Kodaki et al., 1994b) have now identi- 
fied yet another mechanism by which PI3-kinase can be 
activated. It appears that ras, in its activated GTP-bound 
state, can not only activate Raf and subsequently mitogen- 
activated protein kinase, but it also can interact and asso- 
ciate directly with PI3-kinase, leading to enhanced activa- 
tion and increased production of 3-phosphorylated lipids 
in intact cells. In addtion, N17 dominant negative ras leads 
to a 5-fold decrease in the levels of Ptdlns(3,4,5)Pa induced 
by epidermal growth factor (EGF) (Rodriguez-Viciana et 
al., 1994), suggesting that in intact cells, ras is a major 
regulator of 3-phosphorylated lipid production. 
Finally, it is a fair bet that an important tool in the clarifica- 
tion of Ptdlns(3,4,5)P3 function will be the fungal metabo- 
lite, wortmannin. This compound, at suitably low concen- 
trations, seems to be a remarkably specific inhibitor of 
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Pl3-kinase (Arcaro and Wymann, 1993) but not of yeast 
or mammalian PI3-kinase (Stephens et al., 1994b). In addi- 
tion to being a useful experimental compound, it will surely 
be looked at again from a pharmaceutical angle, this time 
with the idea of exploiting these signaling pathways. 
Ptdlns(4,5)P2 and the Cytoskeleton 
As Janmey (1994) has pointed out in his recent review 
on the interactions of polyphosphoinositol lipids and the 
cytoskeleton, tight binding of these lipids to proteins has 
been known for a long time and may involve a wide range 
of components of the cytoskeletal system. The strongest 
and most studied interactions, with ~.heir physiological end- 
points most clearly indicated, are those first discovered, 
i.e., the interactions of Ptdlns(4,5)P2 with gelsolin and 
with profilin (Lassing and Lindberg, 1985; Janmey and 
Stossel, 1987). 
Following the initial discovery of these interactions, it 
would be fair to say that there was considerable skepticism 
about their significance among the inositide signaling 
community. This was for several reasons, but in particular 
because of the absence of any evidence of specificity in 
the binding (as there is no suitable control) and the diffi- 
culty in accepting that the receptor-mediated hydrolysis 
of inositol lipids would be important in these processes. 
(In other words, Ptdlns(4,5)P2 would seem to have enough 
to do as a precursor to Ins(1,4,5)P3, DAG, and now Ptdlns 
(3,4,5)P3, and for it to do something else as well seemed 
to make excessive demands on the ability of the cell to 
regulate functions independently). 
However, there is now an increasing realization that ino- 
sitides in the cytoskeleton are probably a separate issue 
entirely from those in the plasma membrane. The enzymes 
responsible for their synthesis are in part bound to the 
cytoskeleton, an interaction that can be changed upon cell 
activation (Payrastre et al., 1991). Also, it has become 
apparent that the synthesis of the polyphosphoinositol lip- 
ids can be controlled directly by receptors and is not just 
an indirect consequence of PIC activation (Stephens et 
al., 1993b). Thus, the regulation of inositide kinases in the 
cytoskeleton is something that can now be considered as 
a system separate from those in the plasma membrane. 
Thus far, much of the work carried out on the regulation 
of cytoskeletal elements by polyphosphoinositides has fo- 
cused on in vitro characterization of binding sites on com- 
ponents such as gelsolin, profilin, and cofilin (reviewed 
by Janmey, 1994). In a farsighted review, Lassing and 
Lindberg (1988) had already suggested that Ptdlns(4)P/ 
Ptdlns(4,5)P2 bound to profilin could inhibit he production 
of profilactin complexes and therefore could release 
monomeric actin able to form new filaments. 
Perhaps the most enticing piece of evidence for a role of 
Ptdlns(4,5)P2 bound to profilin in the control of cytoskeletal 
events comes from some elegant work carried out by the 
Wigler group (Vojtek et al., 1991) using a yeast mutant in 
cyclase-associated protein (CAP). CAP is a bifunctional 
protein required for both RAS signaling to the adenylyl 
cyclase complex and an adenylyl cyclase-independent 
pathway. The CAP mutant phenotype is associated with 
both nutritional and morphological defects, and Vojtek et 
al. (1991) screened for genes able to suppress the second 
phenotype. Profilin was identified in this screen. Compari- 
son of the homology of yeast profilin with profilins from 
Acanthamoeba revealed two limited homology boxes, and 
mutations introduced into these boxes lead to a decrease 
in the ability of the yeast profilin to suppress the CAP mu- 
tant. However, biochemical analysis revealed that all mu- 
tant profilins bound actin with an affinity similar to that 
of wild-type profilin, suggesting that another function of 
profilin was important in complementing CAP. Vojtek et 
al. (1991) therefore investigated the ability of the two iso- 
forms of profilin from Acanthamoeba to suppress the CAP 
phenotype, and they demonstrated that, by far, the most 
effective was profilin isOform II, which (although highly ho- 
mologous to isoform I) has a 10- to 50-fold higher affinity for 
Ptdlns(4,5)P2 (Machasky et al., 1991). The demonstration 
that CAP is also present in pig platelets and is an actin- 
binding protein (Gieselmann and Mann, 1992) suggests 
that a similar signal transduction pathway may exist in 
mammals. 
For the profilin-Ptdlns(4,5)P2 interaction to be an im- 
portant link in the PI cycle and the regulation of actin fila- 
ments, Lassing and Lindberg (1988) had suggested that 
PIC would be able to recognize and hydrolyze Ptdlns(4,5)P2 
bound to profilin. A number of years later, Goldschmidt- 
Clermont et al. (1991) demonstrated not only that profilin 
inhibited PIC from hydrolyzing Ptdlns(4,5)P2, but also that 
this inhibition was relieved by phosphorylation of PIC. 
Thus, the ideas of Lassing and Lindberg (1988) have been 
vindicated and suggest a way in which Ptdlns(4,5)P2 hy- 
drolysis may lead to a remodeling of the cytoskeleton. 
Under resting conditions, PIC would be unable to hy- 
drolyze Ptdlns(4,5)P2 owing to its protection by profilin. 
However, profilin-Ptdlns(4,5)P2 could be hydrolyzed fol- 
lowing receptor stimulation, leaving profilin able to interact 
with actin filaments and perhaps lead to their breakdown 
and the production of profilin-actin complexes. Resynthe- 
sis of Ptdlns(4,5)P2 could then occur, as has been sug- 
gested by the demonstration that a number of lipid ki- 
nases, including Ptdlns(4)P 5-kinase, translocate to the 
cytoskeleton after receptor activation (Payrastre et al., 
1991). We should of course stress that Ptdlns(4,5)P2 me- 
tabolism by PIC is by no means the only way in which 
this cytoskeletal remodeling could occur. Agonists such as 
insulin have also been demonstrated to lead to a change in 
actin polymerization, probably through the activation of 
small molecular weight G proteins such as rac/rho (Ridley 
et al., 1992), and the possibility of 3-phosphorylated inosi- 
tol lipid involvement (Zhang et al., 1992) is one to be ex- 
plored further. With regard to rho and the cytoskeleton, 
the recent suggestion by Chong et al. (1994) that rho can 
regulate Ptdlns(4)P 5-kinase provides a potential mecha- 
nism for regulation of Ptdlns(4,5)P2 levels. 
Finally, some elegant work identifying the binding sites 
for Ptdlns(4,5)P2 on gelsolin and villin (Janmey et al., 1992) 
has shown that this is unlikely to be a fortuitous binding 
to a grouping of positively charged amino acids, but rather 
that it is probably a specific interaction. It will be fascinat- 
ing, when Ptdlns(3,4)P2 and Ptdlns(3)P become available 
in quantity, to explore the isomeric specificity of this bind- 
ing. And as the families of inositol lipid kinases grow, we 
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view it as an increasingly enticing prospect that some of 
these could be specifically associated with the cytoskele- 
ton and differentially regulated, for a purpose separate 
from what is currently regarded as "classic" inositol lipid 
signaling. 
The Nuclear Inositide Cycle 
This appears to us to be currently the most enigmatic as- 
pect of inositide function. We have summarized elsewhere 
the evidence for the existence of a nuclear inositide cycle 
(Divecha et al., 1993), which in its basic biochemistry (the 
controlled hydrolysis of Ptdlns(4,5)P2 and possibly also 
Ptdlns(4)P to DAG and inositol phosphates) resembles 
the plasma membrane inositide cycle. We have indeed 
wondered (Divecha et al., 1993) whether the nucleus was 
the site at which this classic PIC cycle evolved on the 
simple reasoning that if (as we suspect) the nuclear PIC 
cycle plays an important role in some aspect of nuclear 
function at one or more points in the cell cycle, then this 
is likely to have preceded cell surface receptor signaling 
in evolution. 
In the context of the above discussion of inositol lipids 
binding to the cytoskeleton, it is particularly interesting that 
most of the data suggest that the enzymes and lipids of 
the nuclear cycle are all bound to the nuclear skeleton 
rather than being located in the nuclear membrane. In our 
hands (but not those of York and Majerus, 1994), the nu- 
clear membrane must be removed from the nuclei before 
it is possible to detect changes in DAG or Ptdlns(4,5)P2 and 
our interpretation of this has been that it is only inositides 
within the nucleus (not in the detergent-soluble nuclear 
membrane) that are involved in the nuclear inositide cycle 
(Divecha et al., 1993). If the Ptdlns(4,5)P2 that is the sub- 
strate for the nuclear PIC is not in a lipid bilayer, but is 
bound to a protein, then the parallel with the hydrolysis 
of Ptdlns(4,5)P2 bound to profllin, discussed above, is 
obvious. 
What are as yet far from obvious are the answers to 
the key questions that the existence of a nuclear inositide 
cycle poses: how is it controlled, and what is it doing? 
Because coincident with DAG generation in the nucleus 
is a translocation of PKC into the nucleus (Divecha et al., 
1993), we could argue that the answer to the latter question 
is the following: it produces an activated PKC inside the 
nucleus. But that in turn only invokes more questions; e.g., 
how does the cytosolic PKC "see" the nuclear DAG if the 
DAG is not in the nuclear membrane. (And then, how does 
PKC get translocated into the nucleus since there is no 
obvious nuclear translocation signal?) Additionally, what 
is the substrate for PKC once it is in the nucleus in an 
activated state? One group has been building up an im- 
pressive body of evidence for the involvement of PKC II 
in lamin phosphorylation, and recent data (Goss et al., 
1994) have further advanced the idea that lamin B is the 
true physiological substrate by identifying the phosphory- 
lation sites. What is particularly fascinating about this is 
that Goss et al. (1994) suggest that PKC is not in itself 
sufficient to cause nuclear envelope breakdown, but an- 
other kinase (cdc2, perhaps) is probably also required. On 
the other hand, the absence of one lamin phosphorylation 
site in vivo, which PKC does phosphorylate in vitro, leaves 
it open still to discussion whether or not PKC has a physio- 
logical role to play in this process. 
If lamin phosphorylation is indeed a part of nuclear inosi- 
tide function, then it may not be the only one. First, the 
timing of the major rise in nuclear DAG and drop in inositol 
lipids in vivo (Banfib et al., 1993) and in coordinated cell 
cultures (York and Majerus, 1994) is more coincident with 
S phase than with envelope breakdown, suggesting an 
alternative function. Second, Ptlns(4)P and Ins(1,4)P2 can 
activate DNA polymerase ~ in vitro (Sylvia et al., 1988), 
and very recent data from York et al. (1994) showing that 
superinduction of an (apparently partly nuclear) Ins(1,4)P2 
1-phosphatase led to some suppression of DNA synthesis 
are certainly consistent with an intranuclear second mes- 
senger role for Ins(1,4)P2. Third, it is unclear whether the 
Ins(1,4,5)P3 that is apparently involved in nuclear envelope 
reassembly (Sullivan et al., 1993) is produced from cyto- 
solic or from nuclear Ptdlns(4,5)P2; if the latter is indeed 
bound to the nucleoskeleton, there is no a priori reason 
why the nuclear inositide cycle should not be already 
functional even before the nuclear membrane is fully as- 
sembled. 
We do not yet know whether all production of DAG within 
the nucleus is from inositides or whether other lipids con- 
tribute. Jarpe et al. (1994) have shown that phosphatidyl- 
choline (PtdCho) is the major contributor to an increase in 
nuclear DAG, but the nuclei they isolated still had nuclear 
membranes attached, and it is likely that the PtdCho hy- 
drolysis they observed occurred in the nuclear membrane 
rather than within the nucleus. 
PtdCho Hydrolysis 
In this area, the data are currently very confusing; at least 
with Ptdlns(4,5)P2 breakdown, we know that it is a PIC 
that is involved and that the breakdown is probably pre- 
dominantly in the plasma membrane. With PtdCho as a 
source of lipid second messengers, the hydrolysis can be 
by phospholipase A2 (PLA2), PLC, or PLD (Figure 2). It is 
not always clear which one; it may often be all three, and 
we do not know the subcellular location(s). 
PtdCho hydrolysis has recently been extensively re- 
viewed by Exton (1994), and we do not intend to repeat 
this impressive feat here. Instead, to illustrate how prog- 
ress has been made in understanding which phospholi- 
pase hydrolyzes PtdCho in a given situation and why this 
is so confusing, we will focus on a single series of experi- 
ments conducted on NIH 3T3 cells by Cook and Wakelam 
(1992). The background to the experiments was in part 
the observation by Bonser et al. (1989) that phosphatidic 
acid (PtdOH) produced by PLD hydrolysis of PtdCho in 
neutrophils is =trapped" by increasing addition of ethanol 
(such that phosphatidylethanol is produced because etha- 
nol substitutes for water in the nucleophilic attack on the 
phosphodiester bond). The resulting reduction in DAG lev- 
els and the effect on physiological responses should give 
answers to the following questions: how much of the DAG 
generated is actually derived from PtdOH hydrolysis (the 
PtdOH having been first produced by PLD [ethanol does 
Review: Phosholipid Signaling 
273 
PLA 1 
H = 
II 
-o -o -N  
?, 
H- -C- -O  mC- - I -~  
,9. '(3' OH3 
 LA2 L, 
C O P O - -CH2CH2~N- -  OH 3 
oH ! , CH3 
PLC PLD 
Figure 2. Hydrolysis of PtdCho 
A schematic structure ofPtdCho is depicted, with the sites of cleavage 
by hydrolytic phospholipids illustrated. R1 and R2 are hydrocarbon 
chains of long chain fatty acids. 
not effect DAG generation by PLC; see Figure 2]); and 
how essential is this DAG or PtdOH to the physiological 
endpoint? In the neutrophil (Bonser et al., 1989), the an- 
swers were reasonably clear: sufficient ethanol to max- 
imize phosphatidylethanol production from PtdCho (but 
with no effect of Ptd(4,5)P2 hydrolysis) completely inhibited 
DAG production from PtdCho and it also inhibited superox- 
ide generation. This suggested that all the DAG was de- 
rived via PLD (such that there is little PLC activity on 
PtdCho), and it also suggested that PLD activation was 
an essential part of the physiological response to an ago- 
nist that activates superoxide generation. The latter does 
not of course distinguish between whether the DAG or 
PtdOH is the more important second messenger (subse- 
quent correlative studies imply that PtdOH is the more 
likely of the two [Bauldry et al., 1991]). 
Against this (comparatively) simple background, Cook 
and Wakelam (1992) explored the source of DAG in NIH 
3T3 cells stimulated by three agonists, all of which could 
be shown to activate PLD: tetradecanoyl phorbol acetate, 
bombesin (which interacts with a G protein-linked recep- 
tor), and EGF (whose receptor contains a tyrosine kinase). 
Increasing ethanol in the incubations with tetradecanoyl 
phorbol acetate as the stimulus gave an answer not unlike 
the neutrophils: sufficient ethanol to trap all the PtdOH 
effectively prevented DAG generation from PtdCho. The 
PtdCho source in this system is revealed, as in other sys- 
tems, by fatty acyl profiles (Pettit et al., 1994). However, 
with bombesin, maximal inhibition with ethanol only pre- 
vented 50% of the DAG generation, and with EGF, there 
was virtually no effect of ethanol on stimulated DAG pro- 
duction at all, despite evidence for strong stimulation of 
PLD. Thus, there must also be PLC hydrolysis of PtdCho 
going on independently of PLD activation, but to differing 
degrees depending on the agonist. Even this simple set of 
experiments on one cell type already provides a complex 
picture, and there are still further questions that need to be 
investigated even in this system, such as the subcellular 
location of PtdCho hydrolysis, how hydrolysis is controlled, 
and the physiological functions of DAG and PtdOH. Ex- 
tending the view to the mass of data on other tissues (Ex- 
ton, 1994) emphasizes how far we still have to go. 
Not least of the problems is that we are still at a very 
early stage in our knowledge of the enzymology of PLD 
and PLC, and this is something being addressed now in 
many laboratories. Also, we know that DAG can stimulate 
PKC, but knowing which isozymes (the Ca 2+ independent 
variety, perhaps) and where they are is currently no more 
than guesswork. There are a number of well-explored pos- 
sibilities for what PtdOH may do as an intracellular second 
messenger (e.g., regulation of rasGAP, control of neutro- 
phil superoxide generation, and regulation of actin poly- 
merization [Exton, 1994]), but these are not yet firmly es- 
tablished in vivo. Frequently, there is no obvious control 
for the effects of PtdOH in vitro; would the sn-2,3-enantio- 
mer be a help here? 
With PLA2, our knowledge of the enzymology is more 
extensive, and the control of PLA2 activities by Ca 2+, phos- 
phorylation, and G proteins has also been reviewed re- 
cently (Exton, 1994). The liberation of arachidonic acid 
will engender eicosanoids, and the physiological impor- 
tance of these compounds as autocrine or paracrine regu- 
lators is well established (Piomelli, 1993). What is still not 
very clear is whether arachidonic acid itself is a physiologi- 
cal messenger of importance. That it will stimulate some 
PKC isozymes in vitro is known (Hug and Sarre, 1993), 
but we do not yet know when and where this is relevant 
in vivo. There are also plenty of data suggesting it can act 
as a retrograde second messenger in the nervous system, 
in part by regulating ion channels (Piomelli, 1993). How- 
ever, in most investigations of arachidonic acid function, 
other unsaturated fatty acids (when tried) can do the same 
thing. The unique aspects of arachidonic acid are that it 
Js at a very low resting level in cells compared with these 
other unsaturated fatty acids, it is very much the preferred 
substrate for conversion to eicosanoids, and there is evi- 
dence for arachidonoyl-specific phospholipases. Perhaps 
it is worth a thought, however, that this unusual behavior 
may all be geared solely to its conversion to eicosanoids 
and that the proposed second messenger functions of ara- 
chidonate that do not require such a conversion may 
sometimes be fulfilled physiologically by other unsatu- 
rated fatty acids. 
Finally, it is obvious that PtdCho has been the major 
focus of studies on alternative (i.e., noninositide) sources 
of DAG, PtdOH, and fatty acids. In some systems, ethanol- 
amine lipids (either diacyl or alkenyl versions) have also 
been examined and have been found to be insignificant as 
a source. However, in other studies (Kramer and Deykin, 
1983; McNulty et al., 1991), ethanolamine lipids have been 
suggested to make a significant contribution to DAG, 
PtdOH, or fatty acid generation, and these lipids, in the 
past generally neglected, may be due for a reinvestigation. 
Sphingolipid Signaling 
This is one of the most exciting and unexpected areas of 
phospholipid signaling to emerge in recent years. It has 
been the subject of several reviews (Hannun, 1994; Koles- 
nick and Golde, 1994), and here we can do no more than 
what we have done above for other topics; that is, to sum- 
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marize briefly our own perception of where we stand, and 
to point to what we see as major areas of confusion. Sphin- 
gomyelin is predominantly (but not exclusively; reviewed 
by Koval and Pagano, 1991) a plasma membrane lipid 
and accumulates in large quantities in myelin. Thus, in 
the past, much of the interest in it (as with Ptdlns(4,5)P2 
in the 1960's and 1970's) was as a structural component. 
Only recently has it been perceived as an actively meta- 
bolized lipid with the potential to generate second mes- 
sengers. 
Probably the most burning question is, just how many 
of those messengers are there? (Ptdlns(4,5)P2 certainly 
generates three: Ins(1,4,5)P3, DAG, and Ptdlns(3,4,5)P3, 
with Ins(1,3,4,5)P4 as an optional fourth; thus, there is pre- 
cedence for the generation of multiple messengers). Fig- 
ure 3 shows a schematic structure for sphingomyelin (with 
R being the fatty acyl chain, which, as with all phospholip- 
ids, is variable), and the different boxes show the different 
bits, which we will discuss with respect to potential mes- 
senger functions. Not least of the problems with this area 
is that we do not yet have a full understanding of the cata- 
bolic enzymology that generates these bits of the parent 
molecule. 
The synthesis of sphingomyelin is well summarized in 
other reviews (Koval and Pagano, 1991; Hannun, 1994), 
but we think it would help the reader not familiar with the 
topic to point out that the last stage in de novo synthesis 
of ceramide (which then, in turn, is converted to sphingo- 
myelin by the addition of a phosphocholine moiety) is the 
introduction of the trans-unsaturated bond highlighted by 
the arrow in Figure 3. The available data on the specifici- 
ties of the actions of the various portions of sphingomyelin 
that are discussed below all suggest that homologs lacking 
this trans-unsaturated bond are inactive. Thus, as far as 
we know, the cell does not confuse precursors in de novo 
synthesis with breakdown products; only the latter are 
biologically active. Note that the phosphoinositide signal- 
ing system in general maintains a similar distinction (e.g., 
Ins(1,4,5)P3 is only produced as a second messenger from 
Ptdlns(4,5)P2). However, PtdOH and DAG are both inter- 
mediary metabolites of phospholipid synthesis, as well 
as being generated as second messengers, as described 
above. How the cell avoids confusing the two functions, 
anabolic intermediate versus second messenger, is still 
one of the mysteries of lipid signaling. 
Sphingomyelinase and Ceramide 
Sphingomyelinase catalyzes the parallel reaction to PLC, 
generating ceramide and phosphocholine (Figure 3; re- 
viewed by Hannun, 1994; Hannun and Linardic, 1994; Koles- 
nick and Golde, 1994). Sphingomyelinases are a growing 
family, and it is exciting to anticipate the elucidation f 
molecular structures for this family; will there be G protein- 
and tyrosine kinase-regulated members (as with PIC), 
which are easily identified as such? The clear decrease 
in sphingomyelin that happens when cells are stimulated 
by the appropriate agonist (e.g., tumor necrosis factor 
or interleukin-1 [Kim et al., 1991; reviewed by Hannun, 
1994]), coincident with a parallel and near stoichiometric 
increase in ceramide, is entirely consistent with the activa- 
tion of sphingomyelinase. 
The evidence that ceramide, which could be viewed as 
the sphingolipid counterpart of DAG, is a second messen- 
ger is becoming strong and consistent. The use of a num- 
ber of chemical analogs (which include versions with a 
short fatty acyl chain, a parallel with dioctanoylglycerol 
or oleoylacetylglycerol, to increase accessibility to intact 
cells) has convincingly established a specific role for this 
sphingolipid (Hannun, 1994). The two most promising mo- 
lecular targets for ceramide are a ceramide-stimulated pro- 
tein kinase (Joseph et al., 1993) and a ceramide-stimulated 
protein phosphatase (Dobrowsky et al., 1993; Wolff et al., 
1994). Consideration of the types of agonists that appear 
to activate the sphingomyelin pathway (Hannun, 1994; 
Kolesnick and Golde, 1994) suggests a role for ceramide 
in antiproliferation; these agonists include tumor necrosis 
factor, interferon, interleukin-1, and also vitamin D3 (which 
in HL60 cells induced growth inhibition, followed by the 
induction of differentiation [Okazaki et al., 1990]). Indeed, 
the effect of vitamin D3 was mimicked by the C2 (short 
fatty acyl chain) ceramide analog, which was also found 
to induce differentiation and to lead to the down-regulation 
of c-myc (Wolff et al., 1994). C2 ceramide also mimicked 
the apoptotic response to tumor necrosis factor (~ in U937 
cells (Obeid et al., 1993). 
Some clarification will certainly be required concerning 
whether ceramide is a physiological activator of any PKC. 
H H 
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m(CH2)~2~CH "--CH ~ C--  C - 
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Figure 3. Sphingomyelin 
The schematic structure of sphingomyelin s 
illustrated, with (in color-coded boxes) the frag- 
ments discussed in the text that may have sec- 
ond messenger functions. Ris the hydrocarbon 
chain of a fatty acid. The trans-unsaturated 
bond (see text) is indicated by an arrow. 
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Recent data from Lozano et al. (1994) has implicated PKC~ 
(by the use of dominant negative mutants) in the activation 
of NF-KB by ceramide, one of the most exciting potential 
regulatory influences of sphingolipid signaling. However, 
this in itself illustrates the confusion that can be generated, 
as in this system DAG also (via PKCr~) regulates NF-~B 
and is also generated by tumor necrosis factor ~ stimula- 
tion. So, we still have no idea whether the PtdCho or sphin- 
gomyelin PLC pathway is the controlling factor (i.e., are 
the DAG and ceramide pathways parallel and partly redun- 
dant or are they sequential, and if so, in which order? [see 
SchLitze et al., 1992]). The attraction of the ceramide- 
stimulated protein kinase (Joseph et al., 1993) is that it is 
not sensitive to DAG, suggesting that it is more likely to 
be a target for sphingolipid signaling. Since many of the 
agonists that stimulate sphingomyelinase also stimulate 
PLC activity on PtdCho, it is difficult to dissect these two 
pathways. 
Sphingosine, Sphingosine Phosphate, 
and Sphingosine Phosphochofine 
We consider these together because there is no absolutely 
definitive data as to which (if only one) is the active species 
or if they all are active (there is no reason why they should 
not be; DAG and PtdOH are both considered serious can- 
didates as second messengers). Not least of the confusing 
aspects of sphingosine is the rather large number of 
events that it has been shown to stimulate (e.g., calcium 
release, EGF receptor tyrosine kinase, PLD; Desai et al., 
1993; Olivera et al., 1994). Also, we do not yet have a 
well-established receptor-controlled enzyme(s) that can 
generate sphingosine from sphingomyelin or ceramide. 
Without evidence that both an agonist and sphingosine 
can control the same event and, in addition, that the ago- 
nist can stimulate sphingosine production (i.e., the usual 
chain events that has to be linked for us to begin to accept 
a second messenger), it is difficult o know where to place 
sphingosine. 
Recently, this unfortunate set of circumstances may 
have begun to change. Olivera and Spiegel (1993) have 
shown stimulated production of sphingosine phosphate, 
a mitogenic effect of sphingosine and sphingosine phos- 
phate, and an inhibition of the mitogenic effect of fetal calf 
serum and platelet-derived growth factor (but not EGF, 
which does not stimulate sphingosine phosphate produc- 
tion) by DL-threo-sphingosine (an inhibitor of sphingosine 
kinase), all on the same cells. Also, the stereospecificity 
of sphingosine isomers has very recently been explored 
(Olivera et al., 1994) with regard to its effects on cell 
growth, Ca 2+ release, and stimulated PLD activity (the last 
is thought o be an important part of the action of sphingo- 
sine). The resu Its suggest that some effects of sphingosine 
are stereospecific, whereas others are not, but there is 
sufficient stereospecificity in some responses to make it 
unlikely that the effects of sphingosine are entirely nonspe- 
cific. 
However, thus far, the molecular targets of sphingosine 
and its relatives remain unidentified. Some recent data 
implicate AP-1 in intranuclear events coincident with mito- 
genesis induced by sphingosine (Suet al., 1994), but how 
direct or indirect these effects of sphingosine are has not 
yet been investigated. Also, although sphingosine phos- 
phate is (based on the sphingosine kinase inhibitor data 
above) the most likely candidate for being the active mole- 
cule in vivo, this is not firmly established. For example, 
sphingosinephosphorylcholine is a more potent mitogen 
than sphingosine or sphingosine phosphate (Desai et al., 
1993). Although this may just be because it can enter cells 
more easily, Desai et al. (1993) have suggested it acts by a 
route distinct from sphingosine or sphingosine phosphate. 
Overall, there is a problem in that, thus far, the only way 
to generate sphingosine from sphingomyelin appears to 
be by activating the sphingomyetinase pathway to produce 
ceramide, followed by a ceramidase activity to generate 
sphingosine, and this begs the question of why this path- 
way is antiproliferative insome cells and mitogenic in oth- 
ers. One possibility is that the cells in which ceramide 
is an antiproliferative agent do not contain sphingosine 
kinase pathways, whereas in cells such as Swiss 3T3 fibro- 
blasts, perhaps the receptor activation of a ceramidase 
leads to enhanced production of sphingosine, followed by 
sphingosine phosphate, which could then act mitogeni- 
cally. 
However, with our paucity of information about how cells 
generate sphingosine, which derivative(s) is(are) really the 
active species, and what agonists stimulate their produc- 
tion, a current assessment of how all this fits into the 
scheme of things is very difficult. Yet the influence of sphin- 
golipids and what may be a whole family of new second 
messengers generated from them may be the next boom 
area in intracellular phospholipid signaling. 
PKCs 
The discussion of the activation of this large family of en- 
zymes has been left until the end not least because, one 
way or another, they are involved in almost all of the sec- 
tions discussed above. The PKC family has now been sub- 
divided into three groups: the Ca 2÷ plus DAG requiring 
family, the DAG requiring family, and finally the atypical 
PKCs, which require neither (reviewed by Hug and Sarre, 
1993). In fact, the three subdivisions fit nicely into some 
of the signal transduction pathways already outlined: the 
classical PI pathway, which generates DAG and Ca 2÷, 
would obviously activate the first group, while PtdCho/PLC 
or PLD hydrolysis of PtdCho leading to just DAG would 
only activate the second group. Activation of the third 
group could be carried out by either the Ptdlns(3,4,5)P3 
pathway (Nakanishi et al., 1993) or the ceramide pathway 
(see above). Although there is evidence for all these sec- 
ond messengers activating members of the PKC family, 
in vitro, this does not necessarily reflect what happens in 
vivo. Thus far, we still have a profound lack of knowledge 
as to which isozyme is controlled by what, where it is con- 
trolled, and which substrate(s) it phosphorylates in vivo. 
Not least of the problems is the ability of most PKC iso- 
zymes to be rather promiscuous in vitro with respect to 
both stimulants and substrates and correlating specific 
sites of phosphorylation with those used in vivo (for exam- 
ple, the work of Goss et al. (1994) that we mentioned in 
the section on nuclear inositides) has to be done in order 
to pin a precise physiological substrate on a particular 
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PKC. Nevertheless, the use of dominant negative muta- 
tions, genetic knockout experiments, and overexpression 
are beginning to reveal, in a few instances, some precise 
and specific evidence for the role of particular PKC iso- 
zymes in defined physiological processes (Watanabe et 
al., 1992; Dominguez et al., 1993). 
We discussed above our uncertainties about the loca- 
tion and mechanism of generation of DAG from PtdCho, 
and it is obvious that if we understood that better, we might 
get a bit further in appreciating which PKCs are controlled 
by what. Some recent studies on piatelets show what kind 
of complications we may face (Fukami and Holmsen, 
1995). In these studies, resting platelets (which by stan- 
dard criteria had no PKC activation) showed widely fluctu- 
ating DAG levels, and these were not greatly changed 
on activation by thrombin (which causes PKC activation). 
Only on purifying and analyzing separately all the DAG 
species does it emerge that the stearoyl-arachidonoyl spe- 
cies (derived solely from inositides, perhaps?) is the only 
one that is absent in resting platelets and increases follow- 
ing thrombin stimulation; thus, only that species correlates 
with PKC activation. 
Conclusion 
It is an inevitable consequence of a brief review of a very 
complex and new area that such a review appears rather 
negative and confused; what we do not know is so much 
more than what we do know. But these are enormously 
exciting times in phospholipid signaling. The inositides 
continue to blossom and expand into new territories of cell 
function. PtdCho (and perhaps the ethanol amine lipids?) is 
now unquestionably more than just a structural membrane 
lipid, and the same is now being said about sphingomyelin, 
regarded previously as the very paradigm of a slowly me- 
tabolized piece of membrane architecture. Light is now 
being shed on the functional roles of individual members 
of the PKC family, and an understanding of how this family 
meshes with most of these phospholipid signaling stories 
must surely be approaching. The complexit ies and uncer- 
tainties of phospholipid signaling that we have outlined 
above are merely the sign of a field begin ning the transition 
into full flower, a prospect to be viewed with enthusiasm 
and excitement. 
Acknowledgments 
We are very grateful to our colleagues in the Inositide Laboratory for 
many helpful discussions. N. D. is a Babraham Research Fellow. 
References 
Arcaro, A., and Wymann. M. P. (1993). Wortmannin is a potent phos- 
phatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5- 
trisphcsphate in neutrophil responses. Biochem. J. 296, 297-301. 
Banfi~, H., Zi;~ak, M., Divecha, N., and Irvine, R. F. (1993). Nuclear 
diacylglycerol is increased during cell proliferation in vivo. Biochem. 
J. 290, 633-636. 
Bauldry, S. A., Bass, D. A., Cousart, S. L, and McCale, C. E. (1991). 
Tumor necrosis factor ~ priming of phospholipase D in human neutro- 
phils. Correlation between phosphatidic acid production and superox- 
ide generation. J. Biol. Chem. 266, 4173-4179. 
Berridge, M. J. (1993). Inositol trisphosphate and calcium signalling. 
Nature 361,315-325. 
Bonser, R. W., Thompson, N. T., Randall, R. W., and Garland, L G. 
(1989). Phospholipase D activation is functionally linked to superoxide 
generation in the human neutrophil. Bibchem. J. 264, 617-620. 
Brearly, C. A., and Hanke, D. (1993). Pathway of synthesis of 3,4- and 
4,5-phosphorylated phosphatidylinositols in the duckweed Spirodela 
polyrhiza L Biochem. J. 290, 145-150. 
Carpenter, C. L, Auger, K. R., Duckworth, B. C., Hou, W.-H., Schaff- 
hausen, B., and Cantley, L. (1993). A tightly associated serine/threo- 
nine protein kinase regulates phosphoinositide 3-kinase activity. Mol. 
Cell. Biol. 13, 1657-1665. 
Carter, A. N., Huang, R., Sorisky, A., Downes, C. P., and Rittenhouse, 
S. E. (1994). Phosphatidylinositol 3,4,5-trisphosphate is formed from 
phosphatidylinositol 4,5-bisphosphate in thrombin-stimulated plate- 
lets. Biochem. J. 301,415-420. 
Clapham, D. E. (1995). Calcium signaling. Cell 80, this issue. 
Chong, L. D., Traynor-Kaplan, A., Bokoch, G. M., and Schwartz, 
M. A. (1994). The small GTP-binding protein rho regulates aphosphati- 
dylinositol 4-phosphate 5-kinase in mammalian cells. Cell 79, 507- 
513. 
Cook, J. T., and Wakelam, M. J. O. (1992). Epidermal growth factor 
increases sn-l,2,-diacylglycerol evels and activates phospholipase 
D-catalysed phosphatidylcholine breakdown in Swiss 3T3 cells in the 
absence of inositol-lipid hydrolysis. Biochem. J. 285, 247-253. 
Cunningham, T. W, Lips, D. L., Bansal, V. S., Caldwell, K. K., Mitchell, 
C. A., and Majerus, P. W. (1990). Pathway for the formation of D-3- 
phosphate containing inositol lipids in intact human platelets. J. Biol. 
Chem. 265, 21676-21683. 
Desai, N. N., Carlson, R. O., Mattie, M. E., Olivera, A., Buckley, 
N. E., Seki, T., Brooker, G., and Spiegel, S. (1993). Signalling pathways 
for sphingosylphosphorylcholine-mediated mitogenesis in Swiss 3T3 
fibroblasts. J. Cell Biol. 121, 1385-1395. 
Dhand, R., Hiles, I., Panayotou, G., Roche, S., Fry, M. J., Gout, I., 
Totty, N. F., Truong, O., Vicendo, P., Yonezawa, K., Kasuga, M., Cout- 
neidge, S. A., and Waterfield, M. D. (1994). PI 3-kinase is a dual speci- 
ficity enzyme: autoregulation by an intrinsic protein-serine kinase activ- 
ity. EMBO J. 13, 522-533. 
Divecha, N., Banfi~, H., and Irvine, R. F. (1993). Inositides and the 
nucleus and inositides in the nucleus. Cell 74, 405-407. 
Dobrowsky, R. T., Kamibayashi, C., Mumby, M. C., and Hannun, 
Y. A. (1993). Ceramide activates heterotrimaric protein phosphatase 
2A. J. Biol. Chem. 268, 15523-15530. 
Dominguez, I., Sanz, L., Arrenzana-Seisedos, F., Diaza-Meco, M. T., 
Virelizier, J. L., and Moscat, J. (1993). Inhibition of protein kinase 
subspecies blocks the activation of a NF-KB-like activity in Xenopus 
oocytes. Mol. Cell. Biol. 13, 1290-1295. 
Exton, J. H. (1994). Phosphatidylcholine breakdown and signal trans- 
duction. Biochim. Biophys. Acta 1212, 26-42. 
Fukami, M. H., and Holmsen, H. (1995). Diacylglycerol elevations in 
control platelets unaccompanied by pleckstrin phosphorylation: impli- 
cations for the role of diacylglycerol in platelet activation. Eur. J. Bio- 
chem., in press. 
Gieselmann, R., and Mann, K. (1992). ASP-56, a new actin-sequestedng 
protein from pig platelets with homology to CAP, an adenylate cyclase- 
associated protein from yeast. FEBS Lett. 298, 149-153. 
Goldschmidt-Clermont, P. J., Kim, J. W., Machesky, L. M., Rhee, S.-G., 
and Pollard, T. D. (1991). Regulation of phospholipase C-~,~ by profilin 
and tyrosine phosphorylation. Science 251, 1231-1233. 
Goss, V. L., Hocevar, B. A., Thompson, L J., Stratton, C. A., Burns, 
D. J., and Fields, A. P. (1994). Identification of nuclear I~, protein kinase 
C as a mitotic lamin kinase. J. Biol. Chem. 269, 19074-19080. 
Graziani, A., Ling, L. F., Endemann, G., Carpenter, C. L., and Cantley, 
L. C. (1992). Purification and characterization of human erythrocyte 
phosphatidylinostol 4-kinase. Phosphatidylinositol 4-kinase and phos- 
phatidylinositol 3-monophosphate 4-kinase are distinct enzymes. Bio- 
chem. J. 284, 39-45. 
Hannun, Y. A. (1994). The sphingomyelin cycle and the second mes- 
senger function of ceramide. J. Biol. Chem. 269, 3125-3128. 
Hannun, Y. A., and Linardic, C. M. (1994). Sphingolipid breakdown 
Review: Phosholipid Signaling 
277 
products: anti-proliferative and tumor-suppressor lipids. Biochim. Bio- 
phys. Acta. 1154, 223-236. 
Hawkins, P. T., Jackson, T. R., and Stephens, L. R. (1992). Platelet- 
derived growth factor stimulates ynthesis of Ptdlns(3,4,5)P3 by activat- 
ing a Ptdlns(4,5)P2 3-OH kinase. Nature 358, 157-159. 
Herman, P. K., and Emr, S. D. (1990). Characterization of VPS34, a 
gene required for vacuolar protein sorting and vacuole segregation in 
Saccharomyces cerevisiae. Mol. Cell. Biol. 10, 6742-6754. 
Hiles, I. D., Otsu, M., Volina, S., Fry, M. J., Gout, I., Dhand, R., Panayo- 
tou, G., Ruiz-Larrea, F., Thompson, A., Totty, N. F., Hsuan, J. J., 
Courtneidge, S. A., Parker, P. J., and Waterfield, M. D. (1992). Phos- 
phatidylinositol 3-kinase: structure and expression of the 110 kd cata- 
lytic subunit. Cell 70, 419-429. 
Hug, H., and Sarre, T. F. (1993). Protein kinase C isoenzymes: diver- 
gence in signal transduction? Biochem. J. 291,329-343. 
Janmey, P. A. (1994). Phosphoinositides and calcium as regulators 
of cellular actin assembly and disassembly. Annu. Rev. Physiol. 56, 
169-191. 
Janmey, P. A., and Stossel, T. P. (1987). Modulation of gelsolin func- 
tion by phosphatidylinositol 4,5-bisphosphate. Nature 325, 362-364. 
Janmey, P. A., Lamb, J., Allen, P. G., and Matsudaira, P. T. (1992). 
Phosphoinositide-binding peptides derived from the sequences of gel- 
solin and villin. J. Biol. Chem. 267, 11818-11823. 
Jarpe, M. B., Leach, K. L., and Raben, D. M (1994). (~-Thrombin- 
induced nuclear sn-1,2-diacylglycerols are derived from phosphatidyl- 
choline hydrolysis in cultured fibroblasts. J. Biol. Chem. 33, 526-534. 
Joseph, C. E., Byun, H.-S., Bittman, R., and Kolesnick, R. N. (1993). 
Substrate recognition by ceramide-activated protein kinase. Evidence 
that kinase activity is proline-directed. J Biol. Chem. 268, 20002- 
20006. 
Kapeller, R., and Cantley, L. C. (1994). Phosphatidylinositol 3-kinase. 
Bioessays 16, 565-576. 
Kim, M.-Y., Linardic, C., Obeid, L., and Hannun, Y. (1991). Identifica- 
tion of sphingomyelin turnover as an effector mechanism for the action 
of tumor necrosis factor (~- and y-interferon. J Biol Chem. 266, 484- 
489. 
Kodaki, T., Woscholski, R., Emr, S., Waterfield, M. D., Nurse, P., and 
Parker, P. J. (1994a). Mammalian phosphatidylinositol 3'-kinase in- 
duces a lethal phenotype on expression in Schizosaccharomyces 
pombe: comparison with the VSP34 gene product. Eur. J. Biochem. 
219, 775-780. 
Kodaki, T., Woscholski, R., Hallberg, R., Rodriguez-Viciana, P., Down- 
ward, J., and Parker, P. J. (1994b). The activation of phosphatidylinosi- 
tol 3-kinase by Ras. Curr. Biol. 4, 798-806. 
Kolesnick, R., and Golde, D. W. (1994). The sphingomyelin pathway 
in tumor necrosis factor and interleukin-1 signaling. Cell 77, 325-328. 
Kotani, K., Yonezawa, K., Hara, K., Hiroo, U., Yukari, K., Sakwa, H., 
Ando, A., Chavanieu, A., Calas, B., Grigorescu, F., Nishigama, M., 
Waterfield, M. D., and Kasuga, M. (1994). Involvement of phosphoino- 
sitide 3-kinase in insulin or IGF-l-induced membrane ruffling. EMBO 
J. 13, 2313-2321. 
Kovat, M., and Pagano, R. E. (1991). Intracellular transport and metab- 
olism of sphingomyelin. Biochim. Biophys. Acta 1082, 113-125. 
Kramer, R. M., and Deykin, D. (1983). Arachidonoyl transacylase in 
human platelets. Coenzyme A-indepenc~ent transfer of arachidonate 
from phosphatidylcholine to lysoplasmeny!ethanolamine. J. Biol. Chem. 
258, 13806-13811. 
Lam, K., Carpenter, C. L., Ruderman, N. B., Friel, J. C., and Kelly, 
K. L. (1994). The phosphatidylinositol 3-kinase serine kinase phospho- 
rylates IRS-1. Stimulation by insulin and inhibition by wortmannin. J. 
Biol. Chem. 269, 20648-20652. 
Lassing, I., and Lindberg, V. (1985). Specific interaction between phos- 
phatidylinositol 4,5-bisphosphate and profilin. Nature 314, 472-474. 
Lassing, I., and Lindberg, V. (1988). Evidence that the phosphatidylino- 
sitol cycle is linked to cell motility. Exp. Cell Res. 174, 1-15. 
Lozano, J., Berra, E., Municia, M. M., Diaz-Meco, M. T., Dominguez, 
I., Sanz, L., and Moscat, J. (1994). Protein kinase isoform ~ is critical for 
NF-KB-dependent promoter activation by sphingomyelinase. J Biol. 
Chem. 269, 19200-19202. 
Machasky, L. M., Goldschmidt-Clermont, P. J., and Pollard, T. D. 
(1991). The affinity of human platelet and Acanthamoeba profilin iso- 
forms for polyphosphoinositides account for their relative abilities to 
inhibit phospholipase C. Cell Reg. 1, 937-950. 
McNulty, S., Lloyd, G. S., Rumsby, R. M., Sayner, R. M., and Rumsby, 
M. G. (1991). Ethanolamine is relased from glial cells in primary culture 
on stimulation with foetal calf serum and phorbol ester. Neurosci. Lett. 
139, 183-187. 
Munnik, T., Irvine, R. F., and Musgrave, A. (1994). Rapid turnover of 
phosphatidylinositol 3-phosphate in the green alga Chlamydomonas 
eugamatos: signs of a phosphatidylinositide-3-kinase signalihg path- 
way in lower plants? Biochem. J. 298, 269-273. 
Nakanishi, H., Brewer, K. A., and Exton, J. H. (1993). Activation of 
the ~, isozyme of protein kinase C by phosphatidylinositol 3,4,5-tris- 
phosphate. J. Biol. Chem. 268, 13-16. 
Obeid, L. M., Linardic, C. M., Karotak, L. A., and Hannun, Y. A. (1993). 
Programmed cell death induced by ceramide. Science 259, 1769- 
1771. 
Okazaki, T., Bielawaska, A., Bell, R. M., and Hannun, T. A. (1990). Role 
of ceramide as a lipid mediator of 1 (~ 25-dihydroxyvitamin D3-induced 
HL-60 cell differentiation. J. Biol. Chem. 265, 15823-15831. 
Olivera, A., and Spiegel, S. (1993). Sphinosine-l-phosphate as second 
messenger in cell proliferation induced by PDGF and FCS mitogens. 
Nature 365, 557-560. 
Olivera, A., Zhang, H., Carlson, R. O., Mattie, M. E., Schmidt, R. R., 
and Spiegel, S. (1994). Stereospecificity of sphingosine-induced intra- 
cellular calcium mobilization and cellular proliferation. J Biol. Chem. 
269, 17924-17930. 
Payrastre, B., Van Bergen en Henegouwen, P. M. P., Breton, M., den 
Hartigh, J. C., Plantavid, M., Verkleij, A. J., and Boonstra, J. (1991). 
Phosphoinositide kinase diacylglycerol kinase and phospholipase C 
activities associated to the cytoskeleton: effect of epidermal growth 
factor. J. Cell Biol. 115, 121-128. 
Pettit, T. R., Zaqqa, M., and Wakelam, M. J. (1994). Epidermal growth 
factor stimulates distinct diacylglycerol species generation in Swiss 
3T3 fibroblasts: evidence for a potential phosphatidylcholine-specific 
phospholipase C-catalysed pathway. Biochem. J. 298, 655-660. 
Piomelli, D. (1993). Arachidonic acid in cell signalling. Curr. Opin. Cell 
Biol. 5, 274-280. 
Rhee, S.-G., and Choi, K.-D.(1992). Multiple forms of phospholipase 
C isozymes and their activation mechanisms. In Advances in Second 
Messenger and Phosphoprotein Research, Volume Twenty-Six, J. W. 
Putney, Jr., ed. (New York: Raven Press), pp. 35-61. 
Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., and Hall, 
A. (1992). The small GTP-binding protein rac regulates growth factor- 
induced membrane ruffling. Cell 70, 401-410. 
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, 
B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. (1994). 
Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 
527-532. 
Schetze, S., Potthoff, K., Machleidt, T., Berkovic, D., Wiegmann, K., 
and KrSnke, M. (1992). TNF activates NF-KB by phosphatidylcholine- 
specific phospholipase C-induced "acidic" sphingomyelin breakdown. 
Cell 71,765-776. 
Segal, A. W., and Abo, A. (1993). The biochemical basis of the NADPH 
oxidase of phagocytes. Trends Biochem. Sci. 18, 43-47. 
Stephens, L. R., and Downes, C. P. (1990). Product-precursor relation- 
ship amongst inositol polyphosphates. Biochem. J. 265, 435-452. 
Stephens, L. R., Jackson, T. R., and Hawkins, P. T. (1993a). Agonist- 
stimulated synthesis of phosphatidylinositol (3,4,5)-trisphosphate: a 
new intracellular signaling system? Biochim. Biophys. Acta 1179, 27- 
75. 
Stephens, L. R., Jackson, T. R., and Hawkins, P. T. (1993b). Activation 
of phosphatidylinositol 4,5-bisphosphate supply by agonists and non- 
hydrolysable GTP analogs. Biochem. J. 296, 481-488. 
Cell 
278 
Stephens, L., Smrcka, A., Cooke, F. T., Jackson, T. R., Sternweis, 
P. C., and Hawkins, P. T. (1994a). A novel phosphoinositide 3-kinase 
activity in myeloid-derived cells is activated by G protein I~ 7 subunits. 
Cell 77, 83-93. 
Stephens, L. R., Cooke, F. T., Waiters, R., Jackson, T. R., Violinia, 
S., Gout, I~ D., Waterfield, M. D., and Hawkins, P. T. (1994b). Charac- 
terization of a phosphatidylinositol-specific phosphoinositide 3-kinase 
from mammalian cells. Curr. Biol. 4, 203-214. 
Su, Y., Rosenthal, D., Smalson, M., and Spiegel, S. (1994). Sphingo- 
sine 1-phosphate, a novel signaling molecule, stimulates DNA binding 
activity of AP-1 in quiescent Swiss 3T3 fibroblasts. J. Biol. Chem. 269, 
16512-16517. 
Sullivan, K. M. C., Busa, W. B., and Wilson, K. L. (1993). Calcium 
mobilization is required for nuclear vesicle fusion in vitro: implications 
for membrane traffic and IP~ receptor function. Cell 73, 1411-1422. 
Sylvia, V., Curt.in, G., Norman, J., Stec, J., and Busbee, D. (1988). 
Activation of a low specific activity form of DNA polymerase ~ by inosi- 
tol-l,4-bisphosphate. Cell 54, 651-658. 
Vojtek, A., Haarer, B., Field, J., Gerst, J., Pollard, T. D., Brown, S., 
and Wiglet, M. (1991). Evidence for a functional ink between profilin 
and CAP in the yeast S. cerevisiae. Cell 66, 497-505. 
Watanabe, T., Ono, Y., Taniyama, Y., Hazama, K., Igaraski, K., Ogita, 
K., Kikkawa, U., and Nishizuka, Y. (1992). Cell division arrest induced 
by phorbol ester in CHO cells overexpressing protein kinase C subspe- 
cies. Proc. Natl. Acad. Sci. USA 89, 10159-10163. 
Wennstr6m, S., Hawkins, P. T., Cooke, F., Hara, K., Yonezawa, K., 
Kasuga, M., Jackson, T., Claesson-Welsh, L., and Stephens, L. R. 
(1994). Activation of phosphoinositide 3-kinase is required for PDGF- 
stimulated membrane ruffling. Curt. Biol. 4, 385-393. 
Wolff, R. A., Dobrowsky, R. T., Bielawska, A., Abeid, L. M., and Han- 
nun, Y. A. (1994). Role of ceramide-activated protein phosphatase in 
ceramide-mediated signal transduction. J. Biol. Chem. 269, 19605- 
19609. 
York, J. D., and Majerus, P. W. (1994). Nuclear phosphatidylinositols 
decrease during S-phase of the cell cycle in HeLa cells. J. Biol. Chem. 
269, 7847-7850. 
York, J. D., Saffritz, J. E., and Majerus, P. W. (1994). Inositol phosphate 
1-phosphatase is present in the nucleus and inhibits DNA synthesis. 
J. Biol. Chem. 259, 19992-19999. 
Zhang, J., Dry, M. J., Waterfield, M. D., Jaken, S., Liao, L., Fox, 
J. E. B., and Rittenhouse, S. E. (1992). Activated phosphoinositide 
3-kinase associates with membrane skeleton in thrombin-exposed 
platelets. J. Biol. Chem. 267, 4686--4692. 
